Tissue and endocrine responses to gestrinone and danazol in the treatment of endometriosis

1993 ◽  
Vol 5 (1) ◽  
pp. 103 ◽  
Author(s):  
KL Forbes ◽  
FJ Thomas
Keyword(s):  
Side Effects ◽  
Comparative Study ◽  
Free Fraction ◽  
Effective Alternative ◽  
Treatment Groups ◽  
Alternative Agent ◽  
Similar Range ◽  
Similar Decrease

An open comparative study of gestrinone and danazol in the treatment of endometriosis demonstrated a similar decrease in the extent of active endometriotic deposits, assessed visually following therapy. Biochemical endocrinological changes during therapy with gestrinone showed that basal concentrations of gonadotrophin remained unchanged, oestradiol concentrations varied and the free fraction of testosterone increased. A similar range of side effects was reported in both treatment groups, consisting predominantly of 'androgenic' effects in 10 of 15 women treated with gestrinone and 5 of 12 treated with danazol. The results suggest that gestrinone is an effective alternative agent for the treatment of endometriosis.

Diftalone: A New Non-Steroidal Anti-Inflammatory Agent: Comparative Study with Phenylbutazone in the Treatment of Rheumatoid Arthritis

1977 ◽  
Vol 5 (1) ◽  
pp. 18-25 ◽  
Author(s):  
F Chalem ◽  
P Farias ◽  
H Lizarazo ◽  
P Peña
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Comparative Study ◽  
Clinical Improvement ◽  
Laboratory Tests ◽  
Double Blind Study ◽  
Double Blind ◽  
Treatment Groups ◽  
Inflammatory Agent ◽  
Anti Inflammatory

A double-blind study was carried out to compare the effectiveness and tolerability of diftalone and phenylbutazone in thirty patients with classical or definite rheumatoid arthritis, randomly distributed between the two treatment groups. Both drugs were administered according to a progressively decreasing daily dosage schedule: 1,000 mg during the 1st week; 750 mg the 2nd week and 500 mg from the 3rd week on for diftalone; 400 mg, 300 mg, and 200 mg daily for the 1st, 2nd and from the 3rd week on respectively for phenylbutazone. The study lasted twelve weeks. The clinical controls and laboratory tests were performed weekly up to the 8th week, while the final evaluation was made at the end of the 3rd month. Twelve patients in the group receiving diftalone and fourteen in the phenylbutazone group completed the trial. Clinical improvement was observed in both groups. Effectiveness was somewhat more evident in the diftalone group. Tolerability was acceptable for both drugs, although the diftalone patients showed less frequent and intense side-effects than those treated with phyenylbutazone. No significant differences were found as regards the laboratory parameters, except a significant fall of the E.S.R. (p < 0·05) in the diftalone group. Diftalone seems to be an effective and safe anti-inflammatory agent in the treatment of rheumatoid arthritis.

Synergistic action of propolis with levodopa in the management of Parkinsonism in Drosophila melanogaster

2020 ◽  
Vol 17 (3) ◽  
Author(s):  
Emmanuel Tiyo Ayikobua ◽  
Josephine Kasolo ◽  
Keneth Iceland Kasozi ◽  
Ejike Daniel Eze ◽  
Abass Safiriyu ◽  
...  
Keyword(s):  
Antioxidant Activity ◽  
Drosophila Melanogaster ◽  
Side Effects ◽  
Motor Activity ◽  
Ethanolic Extract ◽  
Synergistic Action ◽  
Content Type ◽  
Treatment Groups ◽  
Ethanolic Extract Of Propolis ◽  
Different Doses

AbstractBackgroundThe Phosphatase and tensin-induced putative kinase 1 (PINK1B9) mutant for Drosophila melanogaster is a key tool that has been used in assessing the pathology of Parkinsonism and its possible remedy. This research was targeted toward determining the effects of ethanolic extract of propolis, with levodopa therapy in the management of Parkinsonism.MethodThe PINK1B9 flies were divided into groups and fed with the different treatment doses of ethanoic extract of propolis. The treatment groups were subjected to 21 days of administration of propolis and the levodopa at different doses after which percentage climbing index, antioxidant activity and lifespan studies were done.ResultsPropolis alone improved motor activity, antioxidant and lifespan in Drosophila melanogaster than in PINK1 flies. Propolis in combination with levodopa significantly (P<0.05) improved physiological parameters at higher than lower concentrations in Parkinsonism Drosophila melanogaster demonstrating its importance in managing side effects associated with levodopa.ConclusionPropolis is a novel candidate as an alternative and integrative medicinal option to use in the management of Parkinsonism in both animals and humans at higher concentrations.

scholarly journals Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1760
Author(s):  
Novella Pugliese ◽  
Marco Picardi ◽  
Roberta Della Pepa ◽  
Claudia Giordano ◽  
Francesco Muriano ◽  
...  
Keyword(s):  
Side Effects ◽  
Hodgkin Lymphoma ◽  
Prognostic Score ◽  
Single Agent ◽  
Response To Therapy ◽  
Baseline Risk ◽  
Historical Cohort ◽  
Treatment Groups

Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare variant of HL that accounts for 5% of all HL cases. The expression of CD20 on neoplastic lymphocytes provides a suitable target for novel treatments based on Rituximab. Due to its rarity, consolidated and widely accepted treatment guidelines are still lacking for this disease. Methods: Between 1 December 2007 and 28 February 2018, sixteen consecutive newly diagnosed adult patients with NLPHL received Rituximab (induction ± maintenance)-based therapy, according to the baseline risk of German Hodgkin Study Group prognostic score system. The treatment efficacy and safety of the Rituximab-group were compared to those of a historical cohort of 12 patients with NLPHL who received Doxorubicin, Bleomycin, Vinblastine, Dacarbazine (ABVD) chemotherapy followed by radiotherapy (RT), if needed, according to a similar baseline risk. The primary outcome was progression-free survival (PFS) and secondary outcomes were overall survival (OS) and side-effects (according to the Common Terminology Criteria for Adverse Events, v4.03). Results: After a 7-year follow-up (range, 1–11 years), PFS was 100% for patients treated with the Rituximab-containing regimen versus 66% for patients of the historical cohort (p = 0.036). Four patients in the latter group showed insufficient response to therapy. The PFS for early favorable and early unfavorable NLPHLs was similar between treatment groups, while a better PFS was recorded for advanced-stages treated with the Rituximab-containing regimen. The OS was similar for the two treatment groups. Short- and long-term side-effects were more frequently observed in the historical cohort. Grade ≥3 neutropenia was more frequent in the historical cohort compared with the Rituximab-group (58.3% vs. 18.7%, respectively; p = 0.03). Long-term non-hematological toxicities were observed more frequently in the historical cohort. Conclusion: Our results confirm the value of Rituximab in NLPHL therapy and show that Rituximab (single-agent) induction and maintenance in a limited-stage, or Rituximab with ABVD only in the presence of risk factors, give excellent results while sparing cytotoxic agent- and/or RT-related damage. Furthermore, Rituximab inclusion in advanced-stage therapeutic strategy seems to improve PFS compared to conventional chemo-radiotherapy.

scholarly journals Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jane L. Tarry-Adkins ◽  
Susan E. Ozanne ◽  
Catherine E. Aiken
Keyword(s):  
Side Effects ◽  
Pregnancy Outcomes ◽  
Gestational Hypertension ◽  
Risk Of Bias ◽  
Maternal Outcomes ◽  
Metformin Treatment ◽  
Eligibility Criteria ◽  
Treatment Groups ◽  
Gastrointestinal Side Effects ◽  
The Impact

AbstractWe systematically assessed the impact of metformin treatment on maternal pregnancy outcomes. PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov and Cochrane databases were systematically searched (inception-1st February 2021). Randomised controlled trials reporting pregnancy outcomes in women randomised to metformin versus any other treatment for any indication were included. Outcomes included gestational weight gain (GWG), pre-eclampsia, gestational hypertension, preterm birth, gestational age at delivery, caesarean section, gestational diabetes, glycaemic control, and gastrointestinal side-effects. Two independent reviewers conducted screening, with a third available to evaluate disagreements. Risk-of-bias and GRADE assessments were conducted using Cochrane Risk-of-Bias and GRADE-pro software. Thirty-five studies (n = 8033 pregnancies) met eligibility criteria. GWG was lower in pregnancies randomised to metformin versus other treatments (1.57 kg ± 0.60 kg; I2 = 86%, p < 0.0001), as was likelihood of pre-eclampsia (OR 0.69, 95% CI 0.50–0.95; I2 = 55%, p = 0.02). The risk of gastrointestinal side-effects was greater in metformin-exposed versus other treatment groups (OR 2.43, 95% CI 1.53–3.84; I2 = 76%, p = 0.0002). The risk of other maternal outcomes assessed was not significantly different between metformin-exposed versus other treatment groups. Metformin for any indication during pregnancy is associated with lower GWG and a modest reduced risk of pre-eclampsia, but increased gastrointestinal side-effects compared to other treatments.

scholarly journals Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Mohamad Javad Yazdanpanah ◽  
Mahnaz Banihashemi ◽  
Fakhrozaman Pezeshkpoor ◽  
Mohammad Khajedaluee ◽  
Sororozaman Famili ◽  
...  
Keyword(s):  
Side Effects ◽  
Cutaneous Leishmaniasis ◽  
Side Effect ◽  
Zinc Sulfate ◽  
Cure Rate ◽  
Meglumine Antimoniate ◽  
Treatment Groups ◽  
Significant Difference

The purpose of this study was to investigate comparison between oral zinc sulfate and meglumine antimoniate in the treatment of cutaneous leishmaniasis (CL). So 100 patients with CL were included and randomly divided into two groups. The first group was treated with oral zinc sulfate (10 mg/kg/day during 45 days period), and the second group was treated with systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days). Acceptable cure after completing 45 days of followup occurred in 30.2% of lesions in first group, while this was 35.5% for the second group. There is not any significant difference between the two treatment groups (P=0.42). Serious side effects resulting in treatment discounting occurred in only meglumine antimoniate group. Although cure rate of systemic meglumine antimoniate group was better the treatment with zinc sulfate is much easier, cheaper, more convenient in consumption, safer, and nearly close cure percentage to systemic meglumine antimoniate injections without serious side effect.

scholarly journals A comparative study to ascertain the efficacy of intravenous dexmedetomidine versus intravenous tramadol to prevent post-operative shivering after laparoscopic surgery

2019 ◽  
Vol 6 (3) ◽  
pp. 713
Author(s):  
Kishore K. ◽  
Syed Ali Aasim ◽  
Manish Kumar J.
Keyword(s):  
Laparoscopic Surgery ◽  
Side Effects ◽  
Comparative Study ◽  
General Anaesthesia ◽  
Power Number ◽  
Group Iii ◽  
Group I ◽  
Number Of Patients ◽  
Envelope Method ◽  
Level Of Significance

Background: Shivering is commonly encountered both after regional and general anaesthesia (GA) with a little higher incidence in patients receiving GA. The aim of study was to compare the effectiveness of dexmedetomidine and tramadol in decreasing postoperative shivering in patients undergoing laparoscopic surgery.Methods: Total 120 patients were included in this study. In order to get a 5% level of significance and 80% power number of patients required in each group was 40, with a total of 120 patients. Randomization of groups was done based on closed envelope method. Patients were allocated into three groups group I, II and III of 40 patients each. Patients in group I and group II were administered 0.75 μg/kg of dexmedetomidine and 1.5 mg /kg of tramadol in 100 ml NS respectively half a before extubation, while patients in group III did not receive any pharmacological intervention.Results: All three groups were comparable regarding distribution of age, gender, ASA grade and temperature at beginning and end of surgery and were non-significant.Conclusions: Dexmedetomidine seems to possess anti-shivering properties and was found to reduce the occurrence of shivering in patients undergoing general anaesthesia with minimal side effects although its anti-shivering effect was not superior to tramadol.

scholarly journals Comparative Study on Efficacy of Various Types of Exposure Response Prevention Therapies on OCD

2017 ◽  
Vol 4 (2) ◽  
Author(s):  
Mihir Ranjan Nayak ◽  
Narendra nath Samantaray ◽  
Preeti Singh ◽  
Mihir Ranjan Nayak
Keyword(s):  
Comparative Study ◽  
Treatment Outcomes ◽  
Pharmacological Treatment ◽  
Cognitive Restructuring ◽  
Treatment Groups ◽  
Exposure Response ◽  
Exposure Response Prevention ◽  
Management Method ◽  
Exposure Sessions ◽  
Treatment Procedures

Objective: The heterogeneity of OCD has various mixed findings related to the treatment procedures, psychological and pharmacological treatment. Consistent research has shown mixed findings regarding which form of ERP, ERP as Habituation tool or ERP as restructuring tool, is more efficacious. Hence this study is done to examine efficacies of various treatment procedures but importantly to propose a possible treatment choices based on efficacy and acceptability in Indian settings for OCD management. Method: Participants were adult outpatients (N=22) with primary OCD selected  from OPD level and randomly assessed to two treatment groups; a) ERP(Habituation only) with SSRI b) ERP (ERP as restructuring tool) with SSRI. Participants received 12-14 exposure sessions, Result and Conclusions: ERP when used as a process of “habituation” is more efficacious in terms of treatment outcomes but when ERP used as both habituation and cognitive restructuring tool is more tolerable and acceptable by patients and also not prone to dropouts.

scholarly journals Fennel (Foeniculum vulgare) leaf infusion effect on mammary gland activity and kidney function of lactating rats

2019 ◽  
Vol 11 (1) ◽  
pp. 101-105
Author(s):  
NAJDA RIFQIYATI ◽  
ANA WAHYUNI
Keyword(s):  
Uric Acid ◽  
Mammary Gland ◽  
Side Effects ◽  
Kidney Function ◽  
Uric Acid Level ◽  
Acid Level ◽  
Mammary Glands ◽  
Female Rats ◽  
Foeniculum Vulgare ◽  
Treatment Groups

Abstract. Rifqiyati N, Wahyuni A. 2019. Fennel (Foeniculum vulgare) leaf  infusion effect on mammary gland activity and kidney function of lactating rats. Nusantara Bioscience 11: 101-105. Fennel (Foeniculum vulgare Mill) leaf, traditionally, is believed to have a potential in increasing and smoothing breast milk production. This study aimed to determine the effect of fennel leaf infusion on milk production and to know the side effects of its use. The material used in the research was infusion of fennel leaves (Foeniculum vulgare Mill) collected from Kopeng, Central Java. The research utilized 12 female rats each with 5 newborns off springs. The experiment was designed in Completed Random Design (CRD) with 4 treatments and 3 replications. Histological preparation of mammary glands was set using paraffin method with HE staining. Kidney function was observed through uric acid level in the blood. The results showed that the diameter of lactiferous ducts and of its lumen diameter were significantly influenced by 15 days fennel leaf infusion treatment. The largest lactiferous duct diameter observed was on P3 treatment group (452.97 ± 75.033 µm) and the smallest was observed in control groups (273.17 ± 38.746 µm). The numbers of active alveoli observed in treatment groups, i.e., in P1 (20 g/300  mL), P2 (40 g/300  mL), and P3 (60 g/300  mL), increased than inactive alveoli. The blood uric acid level observed was 4.0-4.6 mg/dl. The results suggested that the infusion of fennel leaf with a treatment dose of 60 g infusion in 300  mL distilled water administered for 15 days can significantly increase the diameter of lactiferous lumen of female rat mammary glands, and increase the diameter of the alveoli and the number of active alveolar mammary glands. Histological picture of mammary gland also showed that the female rats treated with dose of 60g infusion per 300  mL aquadest increased milk secretion and than the other treatment groups. The treatment also showed no significant side effects.  

Sign in / Sign up

Export Citation Format

Share Document